Personalized Immunomodulatory Therapy for Atopic Dermatitis: An Allergist’s View
2
조회
0
다운로드
11
인용
0
참고문헌
키워드
초록
The current standard medical therapy for atopic dermatitis (AD) mainly focuses on symptomatic relief by controlling skin inflammation with topical corticosteroids and/or topical calcineurin inhibitors. However, the clinical efficacy of pharmacological therapy is often disappointing to both patients and physicians. The terminology of AD contains a historical meaning of eczematous dermatitis caused by hypersensitivity reaction to environmental inhalant or food allergen. Complex interrelationships among genetic abnormalities, environmental triggers, skin barrier defects, and immune dysfunction resulting in a vicious domino-circle seem to be involved in the development and maintenance of AD. In the viewpoint of AD as an allergic disease, complete avoidance of clinically relevant allergen or induction of specific immune tolerance through administrations of allergen (allergen immunotherapy) can provide clinical remission by breaking the vicious domino-circle maintaining a chronic disease state. In recent clinical studies, monoclonal antibodies including the anti-interleukin-4 receptor antibody and anti-B cell antibody induced significant clinical improvements in patients with AD. The detailed characteristics of immune dysfunction are heterogeneous among patients with AD. Therefore, a personalized combination of immunomodulatory therapies to reduce hypersensitivity (allergen immunotherapy) and correct immune dysfunction (monoclonal antibody therapy) could be a reasonable therapeutic approach for patients with AD. Future immunomodulatory therapies for AD should be developed to achieve long-term treatment-free clinical remission by induction of immune tolerance.
Abstract
The current standard medical therapy for atopic dermatitis (AD) mainly focuses on symptomatic relief by controlling skin inflammation with topical corticosteroids and/or topical calcineurin inhibitors. However, the clinical efficacy of pharmacological therapy is often disappointing to both patients and physicians. The terminology of AD contains a historical meaning of eczematous dermatitis caused by hypersensitivity reaction to environmental inhalant or food allergen. Complex interrelationships among genetic abnormalities, environmental triggers, skin barrier defects, and immune dysfunction resulting in a vicious domino-circle seem to be involved in the development and maintenance of AD. In the viewpoint of AD as an allergic disease, complete avoidance of clinically relevant allergen or induction of specific immune tolerance through administrations of allergen (allergen immunotherapy) can provide clinical remission by breaking the vicious domino-circle maintaining a chronic disease state. In recent clinical studies, monoclonal antibodies including the anti-interleukin-4 receptor antibody and anti-B cell antibody induced significant clinical improvements in patients with AD. The detailed characteristics of immune dysfunction are heterogeneous among patients with AD. Therefore, a personalized combination of immunomodulatory therapies to reduce hypersensitivity (allergen immunotherapy) and correct immune dysfunction (monoclonal antibody therapy) could be a reasonable therapeutic approach for patients with AD. Future immunomodulatory therapies for AD should be developed to achieve long-term treatment-free clinical remission by induction of immune tolerance.
참고문헌 (59)
- Akdis CA, "Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology", American Academy of Allergy, Asthma and Immunology, J Allergy Clin Immunol, pp.2006, 118[DOI]
- Novak N, "Immune mechanisms leading to atopic dermatitis", J Allergy Clin Immunol, 112(6 Suppl), pp.S128~S139 (2003)
- Thomas Bieber, "Atopic Dermatitis", Annals of Dermatology, 22(2), pp.125~137 (2010), 대한피부과학회
- Beck LA, "Dupilumab treatment in adults with moderate-to-severe atopic dermatitis", N Engl J Med, 371, pp.130~139 (2014)
- Simon D, "Anti-CD20 (rituximab) treatment improves atopic eczema", J Allergy Clin Immunol, 121, pp.122~128 (2008)
- Krathen RA, "Failure of omalizumab for treatment of severe adult atopic dermatitis", J Am Acad Dermatol, 53, pp.338~340 (2005)
- Takiguchi R, "Efalizumab for severe atopic dermatitis: a pilot study in adults", J Am Acad Dermatol, 56, pp.222~227 (2007)
- Coca AF, "On the classification of the phenomena of hypersensitiveness", J Immunol, 8, pp.163~182 (1923)
- Sulzberger MB, "Historical notes on atopic dermatitis: its names and nature", Semin Dermatol, 2, pp.1~4 (1983)
- Furue M, "Current status of atopic dermatitis in Japan", Asia Pac Allergy, 1, pp.64~72 (2011)
- Halbert AR, "Atopic dermatitis: is it an allergic disease?", J Am Acad Dermatol, 33, pp.1008~1018 (1995)
- 이해진, "Epidermal Permeability Barrier Defects and Barrier Repair Therapy in Atopic Dermatitis", Allergy, Asthma & Immunology Research, 6(4), pp.276~287 (2014), 대한천식알레르기학회
- Leung DY, "New insights into atopic dermatitis: role of skin barrier and immune dysregulation", Allergol Int, 62, pp.151~161 (2013)
- Raimer SS, "Managing pediatric atopic dermatitis", Clin Pediatr (Phila), 39, pp.1~14 (2000)
- Carroll CL, "The burden of atopic dermatitis: impact on the patient, family, and society", Pediatr Dermatol, 22, pp.192~199 (2005)
- Sanda T, "Effectiveness of house dust-mite allergen avoidance through clean room therapy in patients with atopic dermatitis", J Allergy Clin Immunol, 89, pp.653~657 (1992)
- Werfel T, "Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study", Allergy, 61, pp.202~205 (2006)
- Bousquet J, "Allergen immunotherapy:therapeutic vaccines for allergic diseases. A WHO position paper", J Allergy Clin Immunol, 102, pp.558~562 (1998)
- Bae JM, "Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials", J Allergy Clin Immunol, 132, pp.110~117 (2013)
- Novak N, "Atopic dermatitis-from new pathophysiologic insights to individualized therapy", Allergy, 66, pp.830~839 (2011)
- Genuis SJ, "Sensitivity-related illness: the escalating pandemic of allergy, food intolerance and chemical sensitivity", Sci Total Environ, 408, pp.6047~6061 (2010)
- 이정현, "Relationship Between Indoor Air Pollutant Levels and Residential Environment in Children With Atopic Dermatitis", Allergy, Asthma & Immunology Research, 6(6), pp.517~524 (2014), 대한천식알레르기학회
- Darsow U, "The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study", Allergy, 59, pp.1318~1325 (2004)
- Tupker RA, "Induction of atopic dermatitis by inhalation of house dust mite", J Allergy Clin Immunol, 97, pp.1064~1070 (1996)
- Tan BB, "Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis", Lancet, 347, pp.15~18 (1996)
- Hua TC, "The natural course of early-onset atopic dermatitis in Taiwan: a population-based cohort study", Br J Dermatol, 170, pp.130~135 (2014)
- Johnson EE, "Serum IgE concentration in atopic dermatitis. Relationship to severity of disease and presence of atopic respiratory disease", J Allergy Clin Immunol, 54, pp.94~99 (1974)
- Tao Zheng, "The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma", Allergy, Asthma & Immunology Research, 3(2), pp.67~73 (2011), 대한천식알레르기학회
- Schmitt J, "Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis", J Eur Acad Dermatol Venereol, 21, pp.606~619 (2007)
- Weatherhead SC, "An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema", Br J Dermatol, 156, pp.346~351 (2007)
- Kasperkiewicz M, "Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study", J Allergy Clin Immunol, 127, pp.267~270 (2011)
- Gustafsson D, "Sensitization to food and airborne allergens in children with atopic dermatitis followed up to 7 years of age", Pediatr Allergy Immunol, 14, pp.448~452 (2003)
- Bellou A, "Transfer of atopy following bone marrow transplantation", Ann Allergy Asthma Immunol, 78, pp.513~516 (1997)
- Byremo G, "Effect of climatic change in children with atopic eczema", Allergy, 61, pp.1403~1410 (2006)
- Vähävihu K, "Heliotherapy improves vitamin D balance and atopic dermatitis", Br J Dermatol, 158, pp.1323~1328 (2008)
- Chait I, "Remission of life-long atopic dermatitis after hyposensitisation to house dust mite", Practitioner, 229, pp.609~ (1985)
- Leroy BP, "Injection of allergen-antibody complexes is an effective treatment of atopic dermatitis", Dermatologica, 182, pp.98~106 (1991)
- Tuft L, "Studies in atopic dermatitis. V. Problems in inhalant hyposensitization and results of treatment", J Allergy, 31, pp.1~11 (1960)
- Elias PM, "Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms", J Allergy Clin Immunol, 121, pp.1337~1343 (2008)
- 유호성, "Mutations in the Filaggrin are Predisposing Factor in Korean Children With Atopic Dermatitis", Allergy, Asthma & Immunology Research, 5(4), pp.211~215 (2013), 대한천식알레르기학회
- Suárez-Fariñas M, "Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis", J Allergy Clin Immunol, 132, pp.361~370 (2013)
- Tokura Y, "Extrinsic and intrinsic types of atopic dermatitis", J Dermatol Sci, 58, pp.1~7 (2010)
- Flohr C, "How atopic is atopic dermatitis?", J Allergy Clin Immunol, 114, pp.150~158 (2004)
- Oosting AJ, "Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the Dutch mite avoidance study", J Allergy Clin Immunol, 110, pp.500~506 (2002)
- Tang TS, "Does "autoreactivity" play a role in atopic dermatitis?", J Allergy Clin Immunol, 129, pp.1209~1215 (2012)
- Gendelman SR, "Specific immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system", Ann Allergy Asthma Immunol, 111, pp.555~561 (2013)
- Nouri-Aria KT, "Foxp3 expressing regulatory T-cells in allergic disease", Adv Exp Med Biol, 665, pp.180~194 (2009)
- Miyara M, "Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion", J Allergy Clin Immunol, 123, pp.749~755 (2009)
- Akdis CA, "Mechanisms of allergen-specific immunotherapy", J Allergy Clin Immunol, 127, pp.18~27 (2011)
- Kim HJ, "Effects of Lactobacillus rhamnosus on allergic march model by suppressing Th2, Th17, and TSLP responses via CD4(+)CD25(+)Foxp3(+) Tregs", Clin Immunol, 153, pp.178~186 (2014)
- Weiss ST, "Bacterial components plus vitamin D: the ultimate solution to the asthma (autoimmune disease) epidemic?", J Allergy Clin Immunol, 127, pp.1128~1130 (2011)
- Torii S, "Effects of oral administration of Lactobacillus acidophilus L-92 on the symptoms and serum markers of atopic dermatitis in children", Int Arch Allergy Immunol, 154, pp.236~245 (2011)
- 양현종, "Efficacy of Probiotic Therapy on Atopic Dermatitis in Children: A Randomized, Double- blind, Placebo-controlled Trial", Allergy, Asthma & Immunology Research, 6(3), pp.208~215 (2014), 대한천식알레르기학회
- Sidbury R, "Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study", Br J Dermatol, 159, pp.245~247 (2008)
- 이선아, "Correlation Between Serum Vitamin D Level and the Severity of Atopic Dermatitis Associated With Food Sensitization", Allergy, Asthma & Immunology Research, 5(4), pp.207~210 (2013), 대한천식알레르기학회
- Shoenfeld Y, "The idiotypic network in autoimmunity:antibodies that bind antibodies that bind antibodies", Nat Med, 10, pp.17~18 (2004)
- Schuster SJ, "Vaccination with patient-specific tumor-derived antigen in first remission improves diseasefree survival in follicular lymphoma", Clin Oncol, 29, pp.2787~2794 (2011)
- 남동호, "Autologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: A Preliminary Report", Allergy, Asthma & Immunology Research, 6(1), pp.89~94 (2014), 대한천식알레르기학회
- Nahm DH, "The effects of intramuscular injection of autologous immunoglobulin on clinical severity and serum IgE concentration in patients with atopic dermatitis", Dermatology, 231, pp.145~151 (2015)